International Journal of Colorectal Disease

, Volume 25, Issue 3, pp 401–404

Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery

  • Liliana Bordeianou
  • Hiroko Kunitake
  • Paul Shellito
  • Richard Hodin
Original Article

Abstract

Introduction

A recent study has raised concerns that infliximab treatment, by postpoing surgery for ulcerative and indeterminate colitis patients, may result in a greater need for high-risk emergent or multistep surgical procedures (subtotal colectomies). Our aim was to assess whether infliximab exposure affects rates of subotal colectomy in a large cohort of patients.

Methods

We evaluated 171 consecutive patients with ulcerative or indeterminate colitis who had a total proctocolectomy or a subtotal colectomy between 1993 and 2006 for symptoms of unremitting disease. Forty-four patients (25.7%) received infliximab prior to surgery. We compared the surgical procedures employed on these 44 patients to the surgical procedures employed on the 127 non-infliximab patients, using Fisher’s exact or Student’s t test.

Results

Infliximab exposure did not appear to affect the rate of emergent surgery (4.5% vs 4.4%, p = 0.98), rate of subtotal colectomy (19.2% vs. 18.0%, p = 0.99), or rate of ileoanal J pouch reconstruction (53.8% vs. 62%, p = 0.98). Nor did it affect intraoperative findings of perforation, toxic megacolon, and active disease. The infliximab and non-infliximab cohorts were similar in age, Charlson Comorbidity Index, concomitant steroid use, and albumin levels, although infliximab patients had higher rates of concomitant exposure to 6-mercaptopurine (34.1% vs 16.6%, p = 0.02) and azathioprine (40.9% vs 22.6%, p = 0.02).

Conclusion

Infliximab does not appear to increase rates of emergent surgery or multistep procedures in patients undergoing treatment for ulcerative or indeterminative colitis at our institution.

Keywords

Infliximab Subtotal colectomy Surgical complications Ulcerative colitis 

References

  1. 1.
    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128(4):862–869CrossRefPubMedGoogle Scholar
  2. 2.
    Mor IJ, Vogel JD, Moreira Ada L, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51(8):1202–1207 discussion 1207-1210CrossRefPubMedGoogle Scholar
  3. 3.
    Selvasekar CR, Cima RR, Larson DW et al (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204(5):956–962 discussion 962-953CrossRefPubMedGoogle Scholar
  4. 4.
    Galandiuk S (2007) Discussion. J Am Coll Surg 204:962CrossRefGoogle Scholar
  5. 5.
    Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 4:94CrossRefPubMedGoogle Scholar
  6. 6.
    de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity, a critical review of available methods. J Clin Epidemiol 56(3):221–229CrossRefPubMedGoogle Scholar
  7. 7.
  8. 8.
    Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462–2476CrossRefPubMedGoogle Scholar
  9. 9.
    Lichtenstein GR, Yan S, Bala M, Hanauer S (2004) Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99(1):91–96CrossRefPubMedGoogle Scholar
  10. 10.
    Hancock L, Windsor AC, Mortensen NJ (2006) Inflammatory bowel disease: the view of the surgeon. Colorectal Dis 8(Suppl 1):10–14CrossRefPubMedGoogle Scholar
  11. 11.
    Schluender SJ, Ippoliti A, Dubinsky M et al (2007) Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50(11):1747–1753CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Liliana Bordeianou
    • 1
    • 2
  • Hiroko Kunitake
    • 1
    • 2
  • Paul Shellito
    • 1
    • 2
  • Richard Hodin
    • 1
    • 2
  1. 1.MGH Crohn’s & Colitis CenterHarvard Medical SchoolBostonUSA
  2. 2.Department of SurgeryMassachusetts General HospitalBostonUSA

Personalised recommendations